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The Heart of the Matter*Muthiah Vaduganathan, MD, MPH,y Atheendar S. Venkataramani, MD, PHD,z Deepak L. Bhatt, MD, MPHyO ver the past decade, incremental progresshas been made in reducing mortality ratesin patients with established cardiovascular
disease (CVD) in the United States (1). These favorable
trends largely reﬂect improved uptake of cardiovas-
cular drug and device therapies, streamlined pro-
cesses of care, and augmented access to effective
disease management programs. Collectively, these
secondary prevention approaches have improved the
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paper to disclose.Despite encouraging trends, these data conceal
relatively unaltered trajectories and alarmingly high
rates of cardiovascular risk factors (e.g., dyslipidemia,
hypertension, and diabetes) and adverse health be-
haviors (e.g., physical inactivity, high-calorie diets,
smoking, and nonideal body weights) (1,2). Unfortu-
nately, the proportion of adults and children meeting
all ideal health metrics, as deﬁned by the American
Heart Association (AHA) (3), has not improved in
recent years and is 1% or less in most contemporary
series (4,5). Furthermore, CVD continues to be the
major driver of deaths worldwide, disproportionately
affecting low-income countries (6). As these countries
experience continued transitions in economy, diet,
and disease, it is expected that these patterns in CVD,




Delaying or preventing the development of CVD in at-
risk persons (primary prevention) and reducing the
onset of risk factors in otherwise healthy individuals
(primordial prevention) have only recently become
national and international priorities. The AHA’s 2020
Impact Goal (3), the Institute of Medicine’s report on
“Promoting Cardiovascular Health in the Developing
World” (6), and the Department of Health and Human
Services’ “Million Hearts” Initiative (7) are exemplary
efforts in refocusing attention on early phases of
prevention. However, the practicalities of meeting
these goals are not prescriptive and open questions
remain—who to target, when and where to intervene,
and how to make these efforts sustainable.
High-quality, contemporary clinical trials have
traditionally been limited to primary and secondary
prevention settings. In this issue of the Journal,
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1536Peñalvo et al. (8) present key results from Preschool
SI! (Evaluation of the Program SI! for Preschool Edu-
cation: A School-Based Randomized Controlled Trial),
a comprehensive school-based program intended to
instill favorable health behaviors early in life.SEE PAGE 1525This was a cluster-randomized, parallel-group,
controlled trial of 2,062 children 3 to 5 years of
age enrolled in 24 public schools in Madrid, Spain,
comparing the usual curriculum with a structured
behavioral health program. The intervention pro-
vided educational materials to students, teachers,
schools, and families and focused on multiple com-
ponents of health. Intervention duration varied from
1 to 3 years, depending on the student age at entry.
The primary endpoint of questionnaire-based do-
mains capturing knowledge, attitudes, and habits
improved with intervention, driven by changes in
physical activity and diet. Behavioral improvements
were especially prominent in children who were
maintained in the program for 2 or 3 years. A reduc-
tion in the secondary outcome, triceps skinfold
thickness, was seen in the 3-year intervention group.
The Preschool SI! study (8) adds valuable new
public health data on the beneﬁts of early childhood
intervention. This study uses an innovative design
expanding the role of physicians to encompassFIGURE 1 Building Blocks of Global Cardiovascular Disease Preventi
The health behaviors and cardiovascular risk factors outlined in this ﬁgu
passing ideal cardiovascular health (3).education and community leadership. Furthermore, it
incorporates a structured protocol and evaluative
framework, often lacking in community-based public
health interventions. Finally, the program coordinates
across students, families, and educators, potentially
improving the sustainability of the intervention.
As recognized by the authors (8), a limitation of this
trial is the reliance on self-reported outcomes without
long-term data presented regarding the inﬂuence of
this intervention on objective measures of health be-
haviors and risk factor development. It is unclear
whether this program’s early effects on health knowl-
edge acquisition will translate into long-term (beyond
the intervention period) effects on objective measures
of physical activity, diet, anthropomorphic measure-
ments, and cardiovascular risk factor proﬁles. Further
study is needed of those aspects.
EARLY INTERVENTION: BIOLOGICAL OR
BEHAVIORAL MODULATION?
Converging lines of evidence support the notion that
CVD and the risk of CVD development are determined
early in life (9,10). Although overt CVD often presents
in adulthood, the development of atherosclerosis
and adverse health behaviors begin in childhood.
Preschool SI! targeted a critical age range not only for
the biological underpinnings of CVD, but also for theon and Health Promotion
re are based on American Heart Association–deﬁned metrics encom-
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1537formation of traits that may inﬂuence CVD-related
behaviors (11). The exact mechanism by which Pre-
school SI! achieved its beneﬁcial effects on behavioral
patterns is not entirely clear. How do children as
young as 3 years of age not only assimilate knowledge
related to their heart and health, but then in turn
change their behavioral patterns favorably?
The observed beneﬁts in Preschool SI! may be
driven by behavioral modulation at the level of the
student, school, or family. Understanding these
behavioral changes will facilitate how this program
can be scaled elsewhere and shed light on the exact
mechanisms to inform the design of future global
programs. One potential mechanism is through direct
parental inﬂuence on student behavior. Because most
children do not exert control over food choice, family
members likely strongly shape any responses to tar-
geted interventions. The beneﬁts seen in Preschool
SI! were greater in families with parents of higher
economic and educational status. Consistent with
these data (8), economically stable families may be
able better to support healthy lifestyles espoused by
the program. Another potentially fascinating mecha-
nism involves the direct effects of the program on
early formation of preferences in these children. In-
terventions targeted during a development period in
childhood when preferences are formed may have
powerful inﬂuences on behaviors later in life. This
preference building may be reinforced through peer
support in this school-based intervention.
Additionally, it is plausible that interventions tar-
geting key sensitive periods in child development
may fundamentally inﬂuence long-term program-
ming of metabolic health. As suggested in the classic
Abecedarian studies, high-quality preschool pro-
grams may strongly affect health and risk behaviorslater in life, especially in poor or at-risk families (12).
Thus, it may not only be the cardiovascular health
information itself that is helpful, but also the cogni-
tive stimulation from and exposure to positive adult
role models, which in turn inﬂuences personality
traits such as delayed gratiﬁcation and impulse con-
trol that are critical for health behavior and habit
formation later in life.
This pioneering study represents an important step
in exploring the intersection of child development,
cardiovascular health promotion, and primordial
prevention. We eagerly await longitudinal follow-up,
data from other age groups, and outcomes related to
families and schools from the Program SI!
NEXT STEPS IN GLOBAL CARDIOVASCULAR
HEALTH PROMOTION
As improvements in CVD mortality plateau in the
United States and the burden of CVD and its risk
factors grow worldwide, new approaches targeting
multiple levels of disease epidemiology need to
be forged (Figure 1). The optimal balance between
secondary, primary, and primordial prevention may
depend largely on region-speciﬁc ecology of CVD, risk
proﬁles, and national resources. Program SI!, standing
for Salud Integral (or comprehensive health), is a
groundbreaking public health program that has
already transformed the delivery and study of high-
impact, cost-effective interventions at the commu-
nity level.
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